Cell and Gene Therapy in Parkinson's Disease Market Size (7MM) is expected to Grow at a Significant CAGR by 2034, estimates DelveInsight

DelveInsight's comprehensive report titled "Cell and Gene Therapy in Parkinson's disease Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Cell and Gene Therapy in Parkinson's disease. The report analyzes the existing treatment practices and unmet medical requirements in Cell and Gene Therapy in Parkinson's disease. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions.

Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Cell and Gene Therapy in Parkinson's Disease Market Size- https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinson-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cell and Gene Therapy in Parkinson's Disease Market Report
• On 29 October 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
• On 23 October 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
• The United States accounted for nearly 46% of the total diagnosed prevalent cases of Parkinson's disease in the 7MM in 2023, which is expected to increase further by 2034.
• As per the insights, the gender distribution of the disease suggests a male predominance, with approximately 54% male cases and 46% female cases in the 7MM in 2023.
• The age-specific distribution of the disease suggests that the age cohort of ≥75 years made the majority of the cases (64%), followed by 65-74 years (22%) in EU4 and the UK in 2023. While there were fewer cases in the age group ≤49 years in EU4 and the UK.
• In 2023, among the 7MM, Japan had the fourth-highest diagnosed prevalent cases, representing around 8% of the total diagnosed cases of Parkinson's disease in the 7MM.
• In 2023, the highest diagnosed prevalent cases of Parkinson's disease were found in Stage III, i.e., around about 1 million cases, followed by Stage IV in the 7MM. An increasing trend is observed throughout the study period (2020-2034).
• The leading Cell and Gene Therapy in Parkinson's Disease Companies such as BlueRock Therapeutics, Prevail Therapeutics, Eli Lilly and Company, MeiraGTx, Hope Biosciences, Sumitomo Pharma, Voyager Therapeutics, Inc., Aspen Neuroscience, and others.
• Promising Cell and Gene Therapy in Parkinson's Disease Therapies such as MeiraGTx, HB-adMSCs, PR001 (LY3884961), and others.

Stay ahead in the competitive landscape of the Cell and Gene Therapy in Parkinson's Disease Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Cell and Gene Therapy in Parkinson's Disease Treatment Market Size- https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinson-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cell and Gene Therapy in Parkinson's Disease Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Stage-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Cell and Gene Therapy in Parkinson's Disease epidemiology trends @ Cell and Gene Therapy in Parkinson's Disease Prevalence- https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinson-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cell and Gene Therapy in Parkinson's Disease Emerging Drugs
• Prevail Therapeutics (Eli Lilly): PR001 (LY3884961)
PR001 is a Cell and Gene Therapy in Parkinson's disease and neuronopathic Gaucher disease. It will be delivered through intra-cisterna magna injection. The GBA1 gene produces the lysosomal enzyme beta-glucocerebrosidase (GCase), which disposes and recycles cellular components. Patients with Parkinson's disease have mutations in their chromosomal copy of GBA1. The PROPEL clinical trial is evaluating the safety of LY3884961 administration in patients with moderate to severe Parkinson's disease with at least one pathogenic GBA1 mutation. The US FDA has granted fast-track designation for PR001 for the treatment of Parkinson's disease with GBA1 mutations.

• MeiraGTx: AAV-GAD
AAV-GAD is an investigational Cell and Gene Therapy in Parkinson's disease treatment market, aiming to enhance GABA production in the brain's subthalamic nucleus. MeiraGTx acquired the therapy from Vector Neurosciences and is currently conducting Phase I/II trials to assess safety and tolerability. Global regulatory discussions for pivotal trial design are ongoing, with a potential pivotal study in 2024. Notably, AAV-GAD is the first gene therapy for PD with an imaging biomarker correlating with clinical improvement.

• Hope Biosciences: HB-adMSCs
Hope Biosciences' HB-AdMSCs are adipose-derived mesenchymal stem cells processed through their proprietary cell culture platform. These pure mesenchymal stem cells, sourced from adult fat, are being developed as cell-based therapeutics for various conditions. Currently, Hope Bio is culturing cells for a Phase II clinical trial authorized by the US FDA and conducted by Hope Biosciences Stem Cell Research Foundation (HBSCRF). This randomized study aims to evaluate the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving activities of daily living and quality of life in individuals with Parkinson's Disease.

Cell and Gene Therapy in Parkinson's Disease Treatment Market
The current treatment landscape for Parkinson's disease lacks a curative therapy, but a combination of pharmacological and non-pharmacological approaches is used to manage symptoms. Physical, occupational, and speech therapies are essential components of the treatment plan. For some patients, surgical options also play a crucial role, and complementary therapies can help address certain symptoms. Various classes of medications are available, with carbidopa/levodopa being the most effective symptomatic treatment, offered in multiple strengths and formulations. Commonly prescribed medications include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists. These drugs primarily aim to reduce motor symptoms or movement-related issues in individuals with Parkinson's disease.

Discover the future of Cell and Gene Therapy in Parkinson's Disease treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Cell and Gene Therapy in Parkinson's Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinson-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cell and Gene Therapy in Parkinson's Disease Therapeutics Market
The current market of Parkinson's disease lacks curative and disease-modifying therapy, leaving symptomatic treatments with a multidisciplinary approach as the only option. Despite several decades of advances in medications and neurosurgical approaches, there remains an unmet need for symptomatic motor control. Better control of tremors, gait and balance, posture, dexterity, and communication skills are major challenges for better therapeutics of Parkinson's disease movement disorder. Further, treatment of psychosis is another unmet need of Parkinson's disease patients."

Scope of the Cell and Gene Therapy in Parkinson's Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Cell and Gene Therapy in Parkinson's Disease Companies- BlueRock Therapeutics, Prevail Therapeutics, Eli Lilly and Company, MeiraGTx, Hope Biosciences, Sumitomo Pharma, Voyager Therapeutics, Inc., Aspen Neuroscience, and others.
• Cell and Gene Therapy in Parkinson's Disease Therapies- MeiraGTx, HB-adMSCs, PR001 (LY3884961), and others.
• Cell and Gene Therapy in Parkinson's Disease Therapeutic Assessment: Cell and Gene Therapy in Parkinson's Disease Current Marketed and Parkinson's Disease Emerging Therapies
• Cell and Gene Therapy in Parkinson's Disease Market Dynamics: Cell and Gene Therapy in Parkinson's Disease market drivers and Cell and Gene Therapy in Parkinson's Disease market barriers
• Cell and Gene Therapy in Parkinson's Disease Unmet Needs, KOL's views, Analyst's views, Cell and Gene Therapy in Parkinson's Disease Market Access and Reimbursement

Explore the dynamics of the Cell and Gene Therapy in Parkinson's Disease Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Cell and Gene Therapy in Parkinson's Disease Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/cell-and-gene-therapy-in-parkinson-disease?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1 Key Insights
2 Report Introduction
3 Cell and Gene Therapy in Parkinson's Disease Market Overview at a Glance
4 Epidemiology and Market Methodology
5 Executive Summary
6 Key Events
7 Disease Background and Overview: Parkinson's Disease
8 Epidemiology and Patient Population
9 Patient Journey
10 Emerging Cell and Gene Therapies
11 Cell and Gene Therapy in Parkinson's Disease: Market Analysis
12 Key Opinion Leaders' Views
13 SWOT Analysis
14 Unmet need
15 Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.